Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29496937 | 0.86 | SMN1; SMN2 (0.66) | SMN1; SMN2NPC1MAPTRAB9AALDH1A1 | |
| SCHEMBL5463881 | 0.86 | SMN1; SMN2 (0.66) | SMN1; SMN2NPC1MAPTRAB9AALDH1A1 | |
| SCHEMBL31400272 | 0.86 | ERN1 (0.48) | SMN1; SMN2NPC1MAPTRAB9AALDH1A1 | |
| SCHEMBL21988547 | 0.86 | ERN1 (0.48) | SMN1; SMN2NPC1MAPTRAB9AALDH1A1 | |
| SCHEMBL28422915 | 0.84 | NPC1 (0.47) | SMN1; SMN2NPC1MAPTRAB9AALDH1A1 | |
| SCHEMBL20172587 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1MAPTRAB9AALDH1A1 | |
| SCHEMBL28260148 | 0.78 | NPC1 (0.43) | SMN1; SMN2NPC1MAPTRAB9AALDH1A1 | |
| SCHEMBL31689354 | 0.78 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1MAPTRAB9AALDH1A1 | |
| SCHEMBL29496935 | 0.78 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1MAPTRAB9AALDH1A1 | |
| SCHEMBL2039527 | 0.78 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1MAPTRAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200140413-A1 | WATER-SOLUBLE TRIMETHOXYPHENYLPYRIDINE-TYPE COMPLEXING AGENTS, AND CORRESPONDING LANTHANIDE COMPLEXES | CISBIO BIOASSAYS (FR) | 2020-05-07 | — | — | US | disclosed |
| EP-3638660-A1 | WATER-SOLUBLE TRIMETHOXYPHENYLPYRIDINE-TYPE COMPLEXING AGENTS, AND CORRESPONDING LANTHANIDE COMPLEXES | CISBIO BIOASSAYS (FR) | 2020-04-22 | — | — | EP | disclosed |
| CN-110997655-A | Water-soluble trimethoxyphenylpyridine complexing agent and corresponding lanthanide complex | CISBIO生物试验公司 | 2020-04-10 | — | — | CN | disclosed |
| CN-110997655-A | Water-soluble trimethoxyphenylpyridine complexing agent and corresponding lanthanide complex | CISBIO生物试验公司 | 2020-04-10 | — | — | CN | disclosed |
| WO-2018229432-A1 | WATER-SOLUBLE TRIMETHOXYPHENYLPYRIDINE-TYPE COMPLEXING AGENTS, AND CORRESPONDING LANTHANIDE COMPLEXES | CISBIO BIOASSAYS (FR) | 2018-12-20 | — | — | WO | disclosed |
| WO-2014147288-A1 | LUMINESCENT TRIAZACYCLONONANE-BASED LANTHANIDE CHELATE COMPLEXES AS LABELLING REAGENTS | KAIVOGEN OY (FI) | 2014-09-25 | — | — | WO | disclosed |
| US-RE36256-E | ADMINISTERING ARYL-SUBSTITUTED QUINOXALINE DERIVATIVES AS ANTIPROLIFERATIVE, ANTICARCINOGENIC AND ANTITUMOR AGENTS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| US-5795889-A | INHIBITING CELL GROWTH WITH ENZYME INHIBITORS FOR SKIN DISORDERS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-08-18 | — | — | US | disclosed |
| EP-0584222-B1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE POULENC RORER INT (US) | 1997-10-08 | — | — | EP | disclosed |
| US-5656643-A | QUINOLIN PYRIDINE DERIVATIVES; USEFUL FOR TREATING CANCER, LEKEMIA, PSORIASIS, INFLAMMATORY DISODERS, BONE DISORDERS, ATHEROSCLEROSIS AND RESTENOSIS; CONTROLLS CELLULAR REPRODUCTION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-08-12 | — | — | US | disclosed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5480883-A | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-01-02 | — | — | US | disclosed |
| US-5409930-A | Inhibits abnoramal cell proliferation; dimethoxyquinoline/ dimethylquinoline/ quinolineoxide/ and quinoxaline derivatives | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-04-25 | — | — | US | disclosed |
| EP-0584222-A4 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE POULENC RORER INT (US) | 1994-07-06 | — | — | EP | disclosed |
| EP-0584222-A1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE. | RHONE POULENC RORER INT (US) | 1994-03-02 | — | — | EP | disclosed |
| WO-1992020642-A1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140413-A1 | WATER-SOLUBLE TRIMETHOXYPHENYLPYRIDINE-TYPE COMPLEXING AGENTS, AND CORRESPONDING LANTHANIDE COMPLEXES | RCC1, LASP1, POT1 | SMN1; SMN2 2250/4885NPC1 4064/4885MAPT 2505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.